ERBB2 and breast cancer: The expression of CCR7 in breast cancer patients was evaluated with respect to age (n = 5), tumor size (n = 5), clinical stage (n = 6), nodal metastasis (n = 7), histological differentiation (n = 7), estrogen receptor expression (n = 6), progesterone receptor expression (n = 4), HER2/neu expression (n = 6), and overall survival (n = 8).